Does Metabolic Dysfunction Affect Liver Fibrosis in Hep B?
Metabolic dysfunction-associated steatotic liver disease (MASLD) was prevalent in more than 40% of patients with chronic hepatitis B and was independently associated with advanced fibrosis.
METHODOLOGY:
This cross-sectional study was conducted at 19 specialised hepatology centres across five European countries to assess the prevalence and risk factors for MASLD and fibrosis.
This study included 1709 consecutive patients with chronic hepatitis B (median age, 53 years; 60.7% men; 57.3% White), defined as the persistence of hepatitis B surface antigen for at least 6 months.
MASLD was diagnosed using ultrasound, histology, and/or transient elastography, with a controlled attenuation parameter score ≥ 275 dB/m with at least one metabolic risk factor.
In patients with chronic hepatitis B and MASLD, advanced fibrosis was defined as liver stiffness measurement values ≥ 8 kPa.
TAKEAWAY:
The prevalence of MASLD in patients with chronic hepatitis B was 42.3% and that of advanced fibrosis was 18%. Advanced fibrosis was more common in those with MASLD than in those without MASLD (25.4% vs 13.7%).
In the multivariate analysis, BMI and type 2 diabetes were independently associated with MASLD in patients with chronic hepatitis B (odds ratio [OR], 1.27; P < .001 and OR, 2.60; P = .03, respectively).
Factors associated with advanced fibrosis in patients with chronic hepatitis B included MASLD (OR, 2.78; 95% CI, 1.50-5.05), BMI (OR, 1.08; 95% CI, 1.02-1.15), insulin treatment (OR, 13.88; 95% CI, 2.95-65.28), and long-term antiviral treatment (OR, 4.86; 95% CI, 2.40-9.85).
MASLD was more common in patients who were on antiviral treatment than in those who were untreated (49.2% vs 44.2%; P = .046). Screening practices for MASLD varied, with 68.4% of centres screened all patients with chronic hepatitis B and 21.1% screened only those with metabolic syndrome and/or steatosis on ultrasound and abnormal liver function tests.
IN PRACTICE:
"The results from our study might genuinely mirror the increase in MASLD cases in Europe that is also reflected in patients with CHB [chronic hepatitis B]," the authors wrote.
SOURCE:
This study was led by Maria Kalafateli and Roberta Forlano, Imperial College London, London, England. It was published online on July 01, 2025, in Clinical Gastroenterology and Hepatology.
LIMITATIONS:
This study was retrospective in nature with missing data from some participating centres. The use of liver stiffness measurement to define advanced fibrosis, despite its modest predictive performance, could have influenced the results. The short duration of longitudinal data collection limited the ability to observe long-term effects of MASLD on chronic hepatitis B outcomes.
DISCLOSURES:
The authors declared having no conflicts of interest. This study did not receive any specific funding, but the Division of Digestive Diseases at Imperial College London received financial support from the National Institute for Health and Care Research Imperial Biomedical Research Centre and one author was a recipient of a Medical Research Council Clinician Scientist award.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
2 hours ago
- Forbes
Liver Cancer Cases Are On The Rise. Here's How To Avoid Getting It
The number of new liver cancer cases will nearly double in the next 25 years, if no public health interventions occur, according to a new global study published in The Lancet. According to the study, there will be more than 1.5 million new cases of liver cancer globally by 2050, up from more than 850,000 in 2022. Liver cancer is not just your typical run of the mill cancer. It currently ranks as the sixth most common cancer worldwide, and the third deadliest. Survival rates are also brim, with 5-year-survival rates ranging from 5-30%, according to HealthDay. Although these alarming trends could represent an emerging global health crisis with profound implications for public health, there is a tremendous amount of hope. According to the aforementioned study, about 60% of liver cancer cases could be prevented by addressing a handful of risk factors. Since the cancer is responsible for killing 700,000 people globally every year, addressing these specific risk factors should be the focus of future public health interventions. The major preventable drivers for liver cancer include Hepatitis B and C, alcohol and liver diseases associated with obesity and metabolic dysfunction. The good news is vaccinations and anti-viral therapies can nearly eliminate one's risk of getting cancer or even acquiring the viral infections of Hepatitis B and C. The Hepatitis B vaccine, for example, which is given usually as three doses during the first two years of life, provides protection against the virus for at least 95% of healthy adults and children, according to the World Health Organization. Similarly, taking an oral pill for 2-3 months can cure nearly 98% of those with Hepatitis C. There could be significant barriers in decreasing liver cancer rates by 2050, particularly because of the high level of vaccine hesitancy that continues to exist globally that has deterred parents from vaccinating their children. Although vaccines remain a safe and effective measure to decrease the risk of disease and death, vaccination rates for many diseases are declining throughout the world. As an example, global coverage for the Hepatitis B vaccine is just 17% in the WHO African region according to the WHO, which is due to not just to access issues but also misinformation and vaccine hesitancy. Another important preventable risk factor for liver cancer is alcohol. This drug is known to result in scarring of the liver, a condition known as cirrhosis which can then lead to liver cancer. Nearly 400 million individuals, or 7% of the world's population aged 15 years and older, live with alcohol use disorder. Even drinking one glass of alcohol per day can increase one's risk of developing liver cancer, according to a study published in Cancer Causes Control. Policy interventions such as taxes on alcoholic beverages, warning labels and bolstering education could significantly decrease alcohol intake and thus prevent liver cancers associated with alcohol intake. Finally, liver diseases associated with obesity are becoming more prevalent in America and globally. Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 40% of individuals globally and is largely associated with obesity and type 2 diabetes. This disease, and thus cancer that could occur from it, is largely preventable with a balanced diet, regular physical activity and weight control. Given how many people are overweight and obese globally, curbing obesity could significantly decrease the projected number of cancers that may occur by the year 2050. Liver cancer is among one of the hardest cancers to treat once advanced, which is reflected in the low 5-year-survival rates. Treatment for it can also be costly and long-term, burdening healthcare systems worldwide. Without acting to increase vaccinations, enforcing alcohol regulations and promoting healthy food environments, the world risks watching a largely preventable disease inflict devastating social and economic consequences worldwide. Prevention isn't just possible- it's essential.
Yahoo
a day ago
- Yahoo
Natera initiates trial of Signatera test for breast cancer
Natera has announced the initiation of the Phase II TEODOR trial of its Signatera test aimed at replacing chemotherapy with endocrine therapy before surgery in certain breast cancer patients. The multicentre, randomised controlled trial (RCT) focuses on women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer who are responsive to endocrine treatment and test negative with Signatera. Academic research organisation Austrian Breast & Colorectal Cancer Study Group sponsored the trial, which plans to enrol 250 subjects across 15 Austrian sites. This trial seeks to assess the endocrine therapy's efficacy in comparison to chemotherapy in those who are Signatera-negative, to minimise the use of pre-operative chemotherapy and its associated side effects. After receiving an endocrine therapy course for four weeks, subjects who remain Signatera-negative and exhibit a favourable response as per the Ki-67 proliferation index measurement are set to be randomised to continue with endocrine therapy or chemotherapy. The primary goal of the TEODOR trial is the response rate to neoadjuvant therapy, gauged by pathological complete response (pCR) and modified Preoperative Endocrine Prognostic Index (PEPI) score, across endocrine and chemotherapy trial arms. Secondary goals encompass long-term effects such as recurrence of breast cancer and overall survival rates. Signatera is a custom-built blood test for identifying molecular residual disease (MRD) in the form of circulating tumour DNA. Natera oncology medical director Angel Rodriguez said: 'With the TEODOR trial, our goal is to identify patients who may be able to safely forgo chemotherapy. 'We are proud to collaborate with ABCSG on this important trial, and we hope this study will support the role of Signatera in guiding neoadjuvant therapy in breast cancer.' The test is covered by Medicare for those with stage IIb and higher breast cancer. In May 2025, Natera announced outcomes from a study assessing the Signatera MRD test in those with soft tissue and bone sarcomas. "Natera initiates trial of Signatera test for breast cancer" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
Experts issue warning after beachcombers make unexpected discovery on US coastline: 'They will continue to spread'
Experts issue warning after beachcombers make unexpected discovery on US coastline: 'They will continue to spread' Beachcombers in Ketchikan, Alaska, found shells of invasive European green crabs on a sandy state park shore in June, making this the newest location in a fight with these harmful non-native species, reported the Alaska Beacon. What's happening? The shells were found during a beach survey June 6 as part of a University of Alaska Southeast class. After this first find, more shells turned up at other spots along Ketchikan's road system. These crabs first showed up in Alaska in 2022 on Annette Island, about 30 miles south of the recent Ketchikan find. The Metlakatla Indian Community has caught around 3,000 of these invasive crabs since they were first spotted, with more than 300 trapped on nearby Gravina Island just last month. "They have continued to spread. They will continue to spread," said Barbara Morgan, a UAS professor who helped lead the beach surveys, per the Beacon. "They are expected to spread through Southeast Alaska, probably most of Southcentral — kind of the southern coast of Southcentral." Why are invasive green crabs concerning? These destructive crabs threaten Alaska's marine ecosystem and fishing industry. They eat salmon fry, young Dungeness crabs, and other native fish species. They also destroy eelgrass beds, which serve as essential habitats for many fish species, including commercially valuable salmon. The National Oceanic and Atmospheric Administration warns Alaskans that green crabs "could potentially damage Alaska's multibillion-dollar fisheries industries, especially for salmon, crab, and mariculture operations." What's being done about invasive species? The Metlakatla Indian Community leads Alaska's most active response effort, establishing a detection program in 2020 that has trapped thousands of green crabs. This "functional eradication" approach focuses on protecting key sites vital to native species, such as salmon and Dungeness crab. The Alaska Invasive Species Partnership coordinates broader work among government agencies, university experts, nonprofits, and community organizations, per the Beacon. It advocates for establishing a stronger state invasive species council to coordinate broader protection and facilitate a quicker response. Bills now in the Alaska Legislature would create such a council. The House approved earlier attempts but didn't reach final approval before the sessions ended, per the Beacon. If you spot what might be a European green crab, you can help by learning to identify them correctly. They have five spikes on each side of their shells and three bumps between their eyes. They can be green, brown, yellow, reddish, or a combination of these colors. Contact your local wildlife office if you spot suspicious crabs or shells. Supporting laws for invasive species control can also help shield Alaska's valuable marine ecosystems and the communities that rely on them. Do you worry about companies drilling too deep into the ground? Definitely Depends on what it's for Only if it's near my home Not really Click your choice to see results and speak your mind. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
